Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial)-Reference-Cited by-同舟云学术

Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial)

Published:2024-05-10 Issue: Volume: Page:
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

Ito Shin,Nakajima Yuri,Fukuda Hiroki,Izumi Chisato,Nakazawa Gaku,Yamashita Hajime,Matsuhisa Hideo,Inoko Moriaki,Toyoda Shigeru,Takiuchi Shin,Kataoka Toru,Izumiya Yasuhiro,Abe Yukio,Sozu Takashi,Sakata Yasushi,Emoto Masanori,Inoue Teruo,Kitakaze Masafumi^ORCID

Funder

Kowa Company

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10557-024-07576-y.pdf

Reference25 articles.

1. Oren O, Goldberg S. Heart failure with preserved ejection fraction: diagnosis and management. Am J Med. 2017;130(5):510–6. https://doi.org/10.1016/j.amjmed.2016.12.031.

2. Nagai T, Yoshikawa T, Saito Y, et al. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction - a report from the Japanese Heart Failure Syndrome with Preserved Ejection Fraction (JASPER) Registry. Circ J. 2018;82(6):1534–45. https://doi.org/10.1253/circj.CJ-18-0073.

3. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202. https://doi.org/10.1001/jama.289.2.194.

4. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61. https://doi.org/10.1056/NEJMoa2107038.

5. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98. https://doi.org/10.1056/NEJMoa2206286.